Article
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials
Registro en:
KATLAMA, C. et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS, v. 23, n. 17, p. 2289-2300, 2009.
1473-5571
10.1097/QAD.0b013e3283316a5e
Autor
Katlama, Christine
Haubrich, Richard
Lalezari, Jacob
Lazzarin, Adriano
Madruga, José V
Molina, Jean-Michel
Schechter, Mauro
Peeters, Monika
Picchio, Gaston
Vingerhoets, Johan
Woodfall, Brian
De Smedt, Goedele
DUET-1 study group
DUET-2 study group
Resumen
Presente no DUET-1: Beatriz Grinsztejn (Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil). To evaluate the efficacy, safety and virologic resistance profile of etravirine (TMC125), a next-generation nonnucleoside reverse transcriptase inhibitor, over 48 weeks in treatment-experienced adults infected with HIV-1 strains resistant to a nonnucleoside reverse transcriptase inhibitor and other antiretrovirals. 2025-08-30